Crossmark

Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance])

Crossref DOI link: https://doi.org/10.1007/s00520-016-3213-3

Published Online: 2016-04-14

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sio, Terence T.

Atherton, Pamela J.

Birckhead, Brandon J.

Schwartz, David J.

Sloan, Jeff A.

Seisler, Drew K.

Martenson, James A.

Loprinzi, Charles L.

Griffin, Patricia C.

Morton, Roscoe F.

Anders, Jon C.

Stoffel, Thomas J.

Haselow, Robert E.

Mowat, Rex B.

Wittich, Michelle A. Neben

Bearden, James D. III

Miller, Robert C.
Funding

Funding for this research was provided by:

National Cancer Institute ((CA-25224, CA-37404, CA-35195, CA- 35269, CA-35431, CA-63848, CA-52352, CA-35101, CA-37417, CA-35267, CA- 63849, CA-35113, CA-35415, CA-35119), (CA31946), (CA33601))
License Information

Text and Data Mining valid from 2016-04-14

Version of Record valid from 2016-04-14
More Information

Article History

Received: 27 November 2015

Accepted: 5 April 2016

First Online: 14 April 2016

Compliance with ethical standards

:

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below